https://mindmedicinelaw.com/briefing/psychedelic-treatment-for-concussions-in-australia-20260614-12951The Psychedelic Journalen2026-06-14T15:04:53.062820+00:00Psychedelic Treatment for Concussions in Australiapsychedelic treatment, concussions, neuroplasticity, Australia, clinical trials, neurological conditions, psilocybin, MDMA, Therapeutic Goods Administration, brain injurieshttps://mindmedicinelaw.com/briefing/impulsivity-and-addiction-neurocognitive-mechanisms-and-treatment-20260613-12882The Psychedelic Journalen2026-06-14T15:05:02.747238+00:00Impulsivity and Addiction: Neurocognitive Mechanisms and Treatmentimpulsivity, addiction, neurocognitive mechanisms, personalized treatment, substance use disorders, neuroplasticity, pharmacological interventions, behavioral interventions, neuromodulationhttps://mindmedicinelaw.com/briefing/ptsd-treatment-consensus-review-key-findings-and-implications-20260612-12886The Psychedelic Journalen2026-06-14T15:05:21.698109+00:00PTSD Treatment Consensus Review: Key Findings and ImplicationsPTSD treatment, cognitive-behavioural therapy, virtual reality therapy, psychodynamic therapy, pharmacotherapy, combination treatment, repetitive transcranial magnetic stimulation, SSRI, SNRI, pediatric PTSDhttps://mindmedicinelaw.com/briefing/neural-basis-of-non-duality-in-meditators-explored-20260612-12833The Psychedelic Journalen2026-06-14T15:05:10.926989+00:00Neural Basis of Non-Duality in Meditators Exploredneural basis, non-duality, meditation, intrinsic neural timescales, consciousness, mental health, EEG, mindfulness, Isha Yoga, advanced meditatorshttps://mindmedicinelaw.com/briefing/esketamine-s-role-in-anesthesia-emotional-benefits-and-cognitive-uncertainty-20260612-12884The Psychedelic Journalen2026-06-14T15:04:43.362434+00:00Esketamine's Role in Anesthesia: Emotional Benefits and Cognitive Uncertaintyesketamine, general anesthesia, perioperative care, depression, anxiety, cognitive function, systematic review, meta-analysis, RCT, clinical protocolshttps://mindmedicinelaw.com/briefing/ampa-receptor-modulation-in-depression-potential-and-challenges-20260612-12721The Psychedelic Journalen2026-06-13T22:04:22.081975+00:00AMPA Receptor Modulation in Depression: Potential and ChallengesAMPA receptor modulation, AMPAkines, rapid-acting antidepressants, glutamatergic system, synaptic plasticity, brain-derived neurotrophic factor, pharmacokinetics, therapeutic window, clinical trials, depression treatmenthttps://mindmedicinelaw.com/briefing/mushroom-bioactives-health-benefits-applications-20260611-12672The Psychedelic Journalen2026-06-13T22:04:29.476301+00:00Mushroom Bioactives: Health Benefits & Applicationsmushroom bioactives, health benefits, neurodegenerative diseases, psychedelic research, functional foods, biomedicine, polysaccharides, antioxidant effects, pharmaceutical research, industrial technology innovationhttps://mindmedicinelaw.com/briefing/optimi-health-s-psilocybin-export-to-uk-a-new-era-in-trials-20260610-13113The Psychedelic Journalen2026-06-14T22:03:52.192324+00:00Optimi Health's Psilocybin Export to UK: A New Era in Trialsoptimi health, psilocybin export, UK clinical trial, psychedelic research, international collaboration, regulatory acceptance, mental health treatment, therapeutic potential, cross-border partnerships, safety protocolshttps://mindmedicinelaw.com/briefing/indonesia-s-drug-court-model-a-shift-in-narcotics-law-20260605-12682The Psychedelic Journalen2026-06-13T22:04:12.246913+00:00Indonesia's Drug Court Model: A Shift in Narcotics Lawindonesia drug policy, drug court model, rehabilitation over incarceration, narcotics law reform, prison overcrowding, public health outcomes